Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma

서지정보

· 발행기관 : 대한이비인후과학회
· 수록지 정보 : 대한이비인후-두경부외과학회지 / 62권 / 12호 / 712 ~ 719페이지
· 저자명 : 권민수, 김대환, 조기주, 김영철, 김진평, 정배권, 이종실, 서지현, 박정제

초록

Background and Objectives This study examined the expressions of p16 and the programmedcell death 1 ligand (PD-L1) in patients with oropharyngeal cancer (OPC) treated withradiotherapy (RT) to identify the correlation between p16 and PD-L1 expression, and to examinethe prognostic significance of these markers for OPC patients receiving RT.
Subjects and Method Forty-eight OPC patients diagnosed and treated at a tertiary referralhospital were enrolled in this retrospective analysis. Patients were initially treated with RT orchemoradiotherapy (CRT) with curative intent and completed the planned schedule. Expressionof p16 and PD-L1 by primary tumors was evaluated by immunohistochemistry, and resultswere interpreted separately and dichotomized according to outcome analyses.
Results Of the 48 patients, 25 (52.1%) expressed p16 and 15 (31.3%) expressed PD-L1. Expressionof these markers showed a mutual positive correlation (p=0.046). Positive PD-L1 expressionwas associated with poor complete remission (CR) rates after RT (p=0.040). Positivep16 expression was associated with better recurrence-free survival (RFS) (p=0.004) but notoverall survival (OS) (p=0.192). PD-L1 expression showed no independent association withsurvival (p>0.05); however, PD-L1 expression tended toward poorer RFS, even in p16-positiveindividuals.
Conclusion There was a positive correlation between the expression of p16 and PD-L1 inOPCs. PD-L1 expression was associated with poorer CR rates after RT or CRT. PD-L1 alonedid not show an association with RFS or OS, but when combined with p16, it tended towardpoorer RFS, even in p16-positive cases.

참고자료

· 없음